Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
The Oncogenic Action of Succinate
Homo sapiens
Disease Pathway
Hypoxia-inducible factor In many tumours, oxygen availability becomes limited (hypoxia) very quickly during cancer development. The major regulator of the response to hypoxia is the HIF transcription factor. Under normal oxygen levels, the protein levels of HIF alpa is very low due to constant degradation, mediated by a sequence of post-translational modification events catalyzed by the enzymes PHD1,2 and 3, (also known as EglN2,1 and 3). Under hypoxic conditions, HIF alpha escapes hydroxylation and degration.
Succinate dehydrogenase (SDH) is a collection of housekeeping genes (SDHA,B,C,D), but mutations in those genes allows for succinate to accumulate and cross the mitochondrial barrier through a dicarboxylate carrier. Once in the cytosol, it inhibits the activity of the PHD1,2 and 3 since succinate is a product of the enzyme, it acts as feedback inhibition.
References
The Oncogenic Action of Succinate References
King A, Selak MA, Gottlieb E: Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene. 2006 Aug 7;25(34):4675-82. doi: 10.1038/sj.onc.1209594.
Pubmed: 16892081
Adam J, Yang M, Soga T, Pollard PJ: Rare insights into cancer biology. Oncogene. 2014 May 15;33(20):2547-56. doi: 10.1038/onc.2013.222. Epub 2013 Jul 1.
Pubmed: 23812428
Zhao T, Mu X, You Q: Succinate: An initiator in tumorigenesis and progression. Oncotarget. 2017 May 10;8(32):53819-53828. doi: 10.18632/oncotarget.17734. eCollection 2017 Aug 8.
Pubmed: 28881853
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Settings